eGFR Slope Tracks Kidney Disease in Cardiovascular Trials eGFR Slope Tracks Kidney Disease in Cardiovascular Trials
A new review proposes using the slope of estimated glomerular filtration rate (eGFR) as a surrogate measure of chronic kidney disease progression in cardiovascular outcome trials.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - January 6, 2022 Category: Transplant Surgery Tags: Nephrology News Source Type: news
Dapagliflozin in Patients With CKD, With and Without HF Dapagliflozin in Patients With CKD, With and Without HF
Heart failure is common in patients with chronic kidney disease. Might the SGLT-2 inhibitor dapagliflozin reduce the risk of kidney failure and cardiovascular death in these patients?JACC: Heart Failure (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - January 3, 2022 Category: Intensive Care Tags: Cardiology Journal Article Source Type: news
Religious service attendance and mortality among adults in the United States with chronic kidney disease - Bruce MA, Thorpe RJJ, Kermah D, Shen J, Nicholas SB, Beech BM, Tuot DS, Ku E, Waterman AD, Duru K, Brown A, Norris KC.
Religion and related institutions have resources to help individuals cope with chronic conditions, such as chronic kidney disease (CKD). The purpose of this investigation is to examine the association between religious service attendance and mortality for ... (Source: SafetyLit)
Source: SafetyLit - December 27, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Dapagliflozin Reduces New-Onset T2D in Patients With CKD, HF Dapagliflozin Reduces New-Onset T2D in Patients With CKD, HF
In patients with chronic kidney disease and heart failure, dapagliflozin curbed the incidence of new-onset type 2 diabetes without reducing HbA1c in a pooled analysis of the DAPA-CKD and DAPA-HF trials.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 21, 2021 Category: Intensive Care Tags: Diabetes & Endocrinology News Source Type: news
Reata Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting of Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome
PLANO, Texas--(BUSINESS WIRE) December 8, 2021 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the“Company,” or“we”), today announced the outcome of the U.S. Food and Drug Administration... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 8, 2021 Category: Drugs & Pharmacology Source Type: news
